Virtus Investment Advisers’s Intellia Therapeutics NTLA Stock Holding History

Virtus Investment Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$457K	Sell	27,019 -3,211	-11%	-$44.9K	0.11%	223
2026 Q1	$388K	Buy	30,230 +737	+2%	+$9.39K	0.11%	249
2025 Q4	$265K	Buy	29,493 +15,866	+116%	+$218K	0.07%	302
2025 Q3	$235K	Buy	13,627 +2,366	+21%	+$29.1K	0.07%	245
2025 Q2	$106K	Sell	11,261 -840	-7%	-$6.9K	0.04%	325
2025 Q1	$86K	Buy	+12,101	New	+$122K	0.02%	443
2022 Q4	–	Sell	-3,452	Closed	-$193K	–	360
2022 Q3	$193K	Buy	+3,452	New	+$214K	0.09%	202

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Virtus Investment Advisers's NTLA Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Intellia Therapeutics (NTLA) stake by 11% in Q2 2026, selling an estimated $44.9K and leaving 27,019 shares worth $457K. The position accounts for 0.11% of the portfolio, ranked #223.

Virtus Investment Advisers first reported a position in NTLA in Q3 2022 and has held it in 7 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Virtus Investment Advisers held 27,019 shares of Intellia Therapeutics worth $457K as of Q2 2026.
Virtus Investment Advisers sold 3,211 Intellia Therapeutics shares in Q2 2026, an estimated $44.9K.
Intellia Therapeutics made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #223 holding.
Virtus Investment Advisers first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 7 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.